Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -70.91%
Price change 2019 → 2020: 1196.88%
Price change 2020 → 2021: -68.43%
Price change 2021 → 2022: 10.69%
Price change 2022 → 2023: -84.14%
Price change 2023 → 2024: -90.74%
Price change 2024 → 2025: -95.89%
Price change 2025 → 2026: 52.00%
Price change 2026 (year to date): 48.60%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.00
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.02
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 84.49% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="GNPX" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Genprex, Inc. | – | 0.00 | – | 🔒 |
| WORK Medical Technology Group Ltd. | – | 0.35 | −28.4 % | – |
| Spineway S.A. | – | 0.07 | +9.3 % | – |
| CompuMed, Inc. | – | 0.23 | +10.2 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by Genprex, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | n/a | 21.0 m | 6.7 m | 1.6 m | 7.8 m |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | n/a | -21.0 m | -6.7 m | -1.6 m | -7.8 m |
| Equity | n/a | 22.3 m | 7.4 m | 1.6 m | 8.0 m |
| Total assets | n/a | 25.1 m | 10.7 m | 4.1 m | 10.2 m |
| Operating cash flow | -14.3 m | -17.8 m | -24.7 m | -17.1 m | -15.3 m |
| Investments (capex) | 83,796 | 59,735 | 71,383 | 0 | 1 |
| Free cash-flow | -14.4 m | -17.8 m | -24.8 m | -17.1 m | -15.3 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | n/a | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.
Valuation and competitors
Genprex, Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Genprex, Inc. | 1.0 m | n/a | 0.0 % |
| InMed Pharmaceuticals Inc. INM | 8.5 m | n/a | -165.1 % |
| Liminatus Pharma, Inc. Class A Common Stock LIMN | 3.4 m | n/a | 0.0 % |
| Biodexa Pharmaceuticals Plc BDRX | 231,248 | n/a | 0.0 % |
| Jaguar Health, Inc. JAGX | 939,338 | n/a | -464.2 % |
| GRI Bio, Inc. GRI | 4.1 m | n/a | 0.0 % |
| BioVie Inc. BIVI | 11.3 m | n/a | 0.0 % |
| CNS Pharmaceuticals, Inc. CNSP | 5.7 m | n/a | 0.0 % |
| Theriva Biologics, Inc. TOVX | 7.6 m | n/a | 0.0 % |
| Sector median (Nasdaq) | 20.8 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Genprex, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 13/11/2026 | -5.30 | -6,160.00 | n/a |
| 30/03/2026 | -25.30 | -286.00 | n/a |
| 14/11/2025 | -109.89 | -275.00 | n/a |
| 08/08/2025 | -187.00 | -15.62 | n/a |
| 12/05/2025 | -285.71 | -55.88 | n/a |
| 01/04/2025 | -462.00 | -18.04 | n/a |
Stock splits
| Date | Operation |
|---|---|
| 16/07/2026 | reverse split: 1 share for 22 |
| 21/10/2025 | reverse split: 1 share for 50 |
| 02/02/2024 | reverse split: 1 share for 40 |
Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Genprex, Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Genprex, Inc.
What is the Genprex, Inc. share price?
Latest recorded price: 2.08 USD on 13/11/2026, for a market cap of 1.1 m USD.
Is Genprex, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US3724463027).
How many employees does Genprex, Inc. have?
15 full-time employees according to the latest published profile.
Who runs Genprex, Inc.?
Ryan M. Confer is the company's chief executive.